Causes of applying Long-Term Care Insurance certification for patients with heart failure with systolic dysfunction

Hiroki Tsuchiya1, Shinya Fujiki1, Takeshi Kashimura1

  • 1Department of Cardiovascular and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Insights

In heart failure patients, non-cardiac conditions are a major reason for Long-Term Care Insurance (LTCI) needs. Understanding these causes improves care management for disabled elderly individuals.

Area of Science:

  • Geriatric Medicine
  • Cardiology
  • Public Health

Background:

  • The aging Japanese society faces a rising number of heart failure patients requiring long-term care.
  • Long-Term Care Insurance (LTCI) use is increasing among disabled elderly individuals, necessitating an understanding of demand drivers.

Purpose of the Study:

  • To investigate the primary causes of Long-Term Care Insurance (LTCI) demand in patients with heart failure with reduced ejection fraction.
  • To inform better care management strategies by identifying the conditions leading to LTCI eligibility.

Main Methods:

  • A retrospective study was conducted in seven hospitals in Niigata City, Japan, from 2011 to 2016.
  • Data from 3738 patients with heart failure with reduced ejection fraction were analyzed, focusing on 312 newly eligible for LTCI.
  • Information on the cause and degree of impairment for LTCI introduction was collected from official registration documents.

Main Results:

  • Nearly half (49.4%) of LTCI demands were due to cardiac diseases, while 50.6% stemmed from non-cardiac conditions.
  • Physical impairment was less severe in the cardiac group compared to major non-cardiac groups (e.g., cancer, stroke, orthopedic conditions).
  • The cancer group exhibited a poorer prognosis than the cardiac group, unlike stroke, orthopedic, or other non-cardiac conditions.

Conclusions:

  • Non-cardiac diseases are a significant factor in LTCI eligibility for heart failure patients, accounting for approximately half of all cases.
  • Identifying the specific causes of disability and LTCI need is crucial for tailoring effective care management.
  • This study highlights the importance of considering multifactorial causes of disability in heart failure patients for optimizing geriatric care.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
424
Documentation in Long-Term and Home Healthcare Setting01:29

Documentation in Long-Term and Home Healthcare Setting

Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
826
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
294